申请人:British Technology Group Limited
公开号:US05604213A1
公开(公告)日:1997-02-18
Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
通式(1)##STR1##中的化合物,其中X代表类固醇的A、B和C环的残基,R代表氢原子或1至4个碳原子的烷基基团,R.sup.14代表氢原子,R.sup.15代表氢原子或1-4个碳原子的烷基或烷氧基团,或2至5个碳原子的羟基或烷基羧酰氧基团,或者R.sup.14和R.sup.15一起代表双键,R.sup.16代表氢原子或1至4个碳原子的烷基基团,以游离碱或药学上可接受的酸盐的形式,用于治疗依赖雄激素的疾病,特别是前列腺癌,以及依赖雌激素的疾病,如乳腺癌。